دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors
Gian Paolo Fadini MD, Stefano Del Prato MD, Angelo Avogaro MD, Anna Solini MD
doi : 10.1111/dom.14599
Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early-phase study
Jennifer Leohr PhD, Christof Kazda MD, Rong Liu PhD, Shobha Reddy BS, Mary Anne Dellva MS, Mark Matzopoulos BS, Mei Teng Loh BS, Thomas Hardy MD, Oliver Klein MD, Christoph Kapitza MD
doi : 10.1111/dom.14561
Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double-blind meal test early-phase study
Christof Kazda MD, Jennifer Leohr PhD, Rong Liu PhD, Shobha Reddy BS, Mary Anne Dellva MS, Mei Teng Loh BS, Thomas Hardy MD, Leona Plum-Mörschel MD
doi : 10.1111/dom.14563
Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add-on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA-PRIME)
Jeff Unger MD, Dale C. Allison MD, Margit Kaltoft MD, Kavitha Lakkole MBA, Jayant K. Panda MD, Chethana Ramesh MSc, Mehmet Sargin MD, Elena Smolyarchuk MD, Melissa Twine BS, Benjamin Wolthers MD, Gizem Yarimbas MSc, Marouan Zoghbi MD, the LIRA-PRIME investigators
doi : 10.1111/dom.14566
Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes
Signe Schmidt MD, Christian S. Frandsen MD, Thomas F. Dejgaard MD, Dorte Vistisen MSc, Thórhallur Halldórsson MSc, Sjudur F. Olsen MSc, Jens-Erik B. Jensen MD, Sten Madsbad MD, Henrik U. Andersen MD, Kirsten Nørgaard MD
doi : 10.1111/dom.14567
Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes
Nicklas J. Johansen MD, Thomas F. Dejgaard MD, Asger Lund MD, Camilla Schlüntz BMSc, Bolette Hartmann PhD, Jens J. Holst MD, Tina Vilsbøll MD, Henrik U. Andersen MD, Filip K. Knop MD
doi : 10.1111/dom.14568
Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis
Xiaodong Hu MD, Yue Yang PhD, Xiaona Hu MD, Xiaomeng Jia MD, Hongzhou Liu MD, Minjie Wei PhD, Zhaohui Lyu MD
doi : 10.1111/dom.14570
A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
Kenichi Furihata MD, Hanaka Mimura MS, Shweta Urva PhD, Tomonori Oura MSc, Kenji Ohwaki PhD, Takeshi Imaoka MD
doi : 10.1111/dom.14572
Effects of dipeptidyl peptidase-4 inhibitors and sulphonylureas on cognitive and physical function in nursing home residents
Andrew R. Zullo PharmD, PhD, Matthew S. Duprey PharmD, PhD, Robert J. Smith MD, Roee Gutman PhD, Sarah D. Berry MD, MPH, Medha N. Munshi MD, David D. Dore PharmD, PhD
doi : 10.1111/dom.14573
Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial
Ulrik Pedersen-Bjergaard DMSc, Rikke M. Agesen MD, Julie M. B. Brøsen MD, Amra C. Alibegovic MD, Henrik U. Andersen DMSc, Henning Beck-Nielsen DMSc, Peter Gustenhoff MD, Troels K. Hansen DMSc, Christoffer Hedetoft MD, Tonny J. Jensen DMSc, Claus B. Juhl DMSc, Andreas K. Jensen MSc, Susanne S. Lerche MD, Kirsten Nørgaard DMSc, Hans-Henrik Parving DMSc, Anne L. Sørensen MSc, Lise Tarnow DMSc, Birger Thorsteinsson DMSc
doi : 10.1111/dom.14574
Vagal afferent cholecystokinin receptor activation is required for glucagon-like peptide-1–induced satiation
Vasiliki Vana PhD, Michelle K. Lærke MSc, Jens F. Rehfeld MD, Myrtha Arnold BSc, Oksana Dmytriyeva PhD, Wolfgang Langhans PhD, Thue W. Schwartz MD, Harald S. Hansen PhD
doi : 10.1111/dom.14575
The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials
Emilie H. Zobel MD, Bernt Johan von Scholten DMSc, Tine W. Hansen PhD, Frederik Persson DMSc, Søren Rasmussen PhD, Benjamin Wolthers PhD, Peter Rossing DMSc
doi : 10.1111/dom.14578
Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom
Joanne Webb BSc, Julie Mount PhD, Lill-Brith von Arx PhD, Jonathan Rachman MBChB, Dionysis Spanopoulos PhD, Robert Wood BSc, Theo Tritton MSc, Olivia Massey BSc, Iskandar Idris DM
doi : 10.1111/dom.14580
Patterns of insulin therapy and insulin daily doses in children and adolescents with type 1 diabetes in Germany
Louisa van den Boom MD, Karel Kostev PhD
doi : 10.1111/dom.14581
A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide
Lai San Tham PharmD, Kevin M. Pantalone DO, Kathleen Dungan MD, Kashif Munir MD, Cheng Cai Tang PhD, Manige Konig MD, Anita Y. M. Kwan MSc
doi : 10.1111/dom.14582
Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial
Meili Cai MD, Xiaowen Shao PhD, Feng Xing PhD, Yuqin Zhang MD, Xinyu Gao MD, Qiongjing Zeng MD, Diliqingna Dilimulati MD, Shen Qu PhD, Manna Zhang PhD
doi : 10.1111/dom.14583
Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials
Yuichiro Yamada MD, Daisuke Yabe MD, Christin Løth Hertz MD, Hiroshi Horio MSc, Jiro Nakamura MD, Anne Møller Nielsen MD, Yutaka Seino MD
doi : 10.1111/dom.14571
Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an ITAS post hoc analysis
Raffaella Buzzetti MD, Riccardo C. Bonadonna MD, Andrea Giaccari MD, Gianluca Perseghin MD, Domenico Cucinotta MD, Carmine Fanelli MD, Angelo Avogaro MD, Gianluca Aimaretti MD, Monica Larosa MSc, Ilaria Pacchetti MSc, Geremia B. Bolli MD
doi : 10.1111/dom.14560
Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial
Thomas R. Pieber MD, Harpreet S. Bajaj MD, Simon R. Heller MD, Ting Jia MD, Kamlesh Khunti PhD, David C. Klonoff MD, Steen Ladelund MSc, Lawrence A. Leiter MD, Lily Wagner MD, Athena Philis-Tsimikas MD
doi : 10.1111/dom.14564
Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis
Petr Borodavkin BSc, William Sheridan BSc, Claudia Coelho MD, Eduard Oštarijaš MD, Zoulikha M. Zaïr MD, PhD, Alexander D. Miras PhD FRCP, Barbara McGowan PhD FRCP, Carel W. le Roux PhD FRCPath, Royce P. Vincent MBBS, MSc, MD(Res), FRCPath, Georgios K. Dimitriadis MD
doi : 10.1111/dom.14565
Influenza vaccination and prognosis for COVID-19 in hospitalized patients with diabetes: Results from the CORONADO study
Alhassane Diallo MD, Matthieu Pichelin PharmD, Matthieu Wargny MD, Pierre Gourdy MD, Jean-Baptiste Bonnet MD, Samy Hadjadj MD, Bertrand Cariou MD, Ariane Sultan MD, Florence Galtier MD, the CORONADO investigators
doi : 10.1111/dom.14577
Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira: A real-world, population-based cohort study
Kevin Cowart PharmD, MPH, Rachel Gonzalez PharmD Student, Nicholas W. Carris PharmD
doi : 10.1111/dom.14579
Longitudinal audit of assessment and pharmaceutical intervention for cardiovascular risk in the Australasian Diabetes Data Network
Claire A. Robertson MBBS, Arul Earnest PhD, Melissa Chee MSc, Maria E. Craig PhD, Peter Colman PhD, Helen L. Barrett MBBS, Philip Bergman MBBS, Fergus Cameron MD, Elizabeth A. Davis PhD, Kim C. Donaghue PhD, P. Gerry Fegan PhD, P. Shane Hamblin MD, D. Jane Holmes–Walker PhD, Craig Jefferies PhD, Stephanie Johnson PhD, Meng T. Mok PhD, Bruce R. King PhD, Richard Sinnott PhD, Glenn Ward MD, Benjamin J. Wheeler PhD, Anthony Zimmermann MBBS, Timothy W. Jones MD, Jenny J. Couper MD, the ADDN Study Group
doi : 10.1111/dom.14584
A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non-specialist needs to know
Mark D. Muthiah MBBS, Ng Cheng Han, Arun J. Sanyal MD
doi : 10.1111/dom.14521
The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment
Bertrand Cariou MD
doi : 10.1111/dom.14651
Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications
Christopher D. Byrne MB BCh, Giovanni Targher MD
doi : 10.1111/dom.14484
Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes
Nick Finer BSc (Hons), MBBS, FRCP
doi : 10.1111/dom.14569
